Table 3.
Parameter estimates of the warfarin original minimal pharmacokinetic model and bootstrap average, 95% confidence interval (CI) and relative standard error (RSE). Only covariate effect parameters with 95% CI excluding 1 are shown
| Parameter | Original | Units | Average | 95% CI | RSE | |
|---|---|---|---|---|---|---|
| POP_CLS | 0.224 | l h–1 | 0.225 | 0.201 | 0.246 | 5% |
| POP_VS | 24.00 | l | 23.88 | 19.70 | 27.70 | 9% |
| POP_CLR | 0.124 | l h–1 | 0.124 | 0.111 | 0.135 | 5% |
| POP_VR | 16.20 | l | 16.11 | 13.29 | 18.61 | 9% |
| POP_TABS | 0.385 | FIXED | ||||
| FAMI_CLS | 0.760 | 0.755 | 0.666 | 0.851 | 6% | |
| FAMI_CLR | 0.872 | 0.868 | 0.789 | 0.954 | 5% | |
| FFLU_CLS | 0.549 | 0.562 | 0.284 | 0.882 | 27% | |
| F2C9_CLS | 0.830 | 0.833 | 0.689 | 0.991 | 10% | |
| F2C9_CLR | 1.230 | 1.234 | 1.020 | 1.470 | 9% | |
| FTYP2_CL | 0.775 | 0.761 | 0.625 | 0.905 | 9% | |
| FFEM_VS | 1.33 | 1.343 | 1.130 | 1.620 | 9% | |
| FFEM_VR | 1.22 | 1.233 | 1.080 | 1.410 | 7% | |
CLS, VS, CLR and VR are per 56.1 kg FFM. POP, population parameter; FAMI, effect of amiodarone on CLS and CLR; FFLU, effect of fluconazole on CLS; F2C9 is the effect of CYP2C9 *1/*3 genotype relative to *1/*1 on CLS and CLR; FTYP2, effect of bioprosthetic valve on CL (similar for both CLS and CLR); FFEM, effect of female sex on V.